PROVIREX Genome Editing Therapies GmbH jobs and careers

About PROVIREX Genome Editing Therapies GmbH

PROVIREX GmbH is a privately-held biotech company developing first-in-class advanced therapy medicinal products (ATMPs). PROVIREX is a spin-off of the Leibniz Institute for Virology (LIV) and is based in Hamburg, Germany. PROVIREX’s technology is based on error-free genome editing for eradication of life-threatening persistent virus infection. PROVIREX employs site-specific recombinase-based genome surgery technology to precisely excise chromosomally integrated viral genomes (proviruses). The major advantage of site-specific recombinases is that they function independently of host DNA repair. Therefore, in contrast to other gene editing technologies, they act with nucleotide precision producing completely error-free recombinants. The engineered recombinase Brec1 excises HIV-1 proviruses with high specificity from the genome of infected cells. PROVIREX’s proprietary Brec1 technology is currently entering clinical testing as first-in-human phase Ib/IIa clinical trials aiming to remove HIV-1 using gene editing of the peripheral blood (hematopoietic) stem cells of people living with HIV. PROVIREX has built GMP-compliant clean rooms at the tecHHub in Hamburg, which have also been approved by GenTSV as S3** laboratories and in which Brec1 technology will be administered as gene therapy in the future. In addition, PROVIREX will also offer CAR-T cancer therapy for people living with HIV, which is unique in Germany! PROVIREX is currently preparing its application for manufacturing authorization with the drug regulatory authority. PROVIREX is also researching ways to administer Brec1 technology more easily and directly, e.g. via LNPs. In another research project, PROVIREX is further developing another recombinase, this time to treat HTLV-1, a retrovirus closely related to HIV that causes an aggressive form of blood cancer and a progressive neurological disease.